Want to see HK:0455 full AI Analyst Report?
0455 Stock Chart & Stats
HK$0.13
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.13
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.08 - HK$0.22
Previous CloseN/A
Volume4.00K
Average Volume (3M)84.94K
Market Cap
HK$184.90M
Enterprise ValueHK$259.20M
Total Cash (Recent Filing)HK$64.81M
Total Debt (Recent Filing)HK$132.66M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage / Balance SheetSustained low-to-moderate debt ratios provide structural financial flexibility. With debt-to-equity near 0.19–0.29, interest burdens and refinancing pressure are limited, allowing the company to fund operations or R&D without immediate solvency stress, supporting multi-month resilience.
Relatively Healthy Gross MarginsGross margins in the low-to-high 40% range create a durable cushion for covering SG&A and product development. Even with compression, these margins imply underlying cost competitiveness or pricing power that can sustain profitability once revenue stabilizes or scales improve over the medium term.
Return To Positive Operating And Free Cash Flow In 2025Resumption of positive operating cash flow and modest free cash flow is a structural inflection point: it reduces dependence on external funding, improves liquidity planning, and gives management runway to prioritize profitable initiatives or service obligations over the coming 2–6 months.
Bears Say
Persistent And Worsening Net LossesDeepening negative net margins indicate structural profitability weaknesses. A widening loss profile erodes retained earnings and limits reinvestment capacity, increasing the likelihood of equity dilution or strategic cutbacks if sustained across quarters, impairing long-term value creation.
Declining Revenue TrendA multi-year revenue decline undermines operating leverage and market position. Falling top-line reduces ability to absorb fixed costs, constrains margin recovery, and signals potential market share erosion or product demand issues that need strategic responses to reverse over the medium term.
Volatile Cash Generation And Prior Deep Negative FCFHistorical swings to negative operating and deeply negative free cash flow create persistent funding risk. Even with 2025 improvements, prior volatility means the company may still require external financing or asset adjustments, raising dilution and execution risk if cash flows re-worsen.
Tianda Pharmaceuticals Ltd. News
0455 FAQ
What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.08 and its highest was HK$0.21 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$184.90M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
Tianda Pharmaceuticals Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 62 days.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Tianda Pharmaceuticals Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.017.
Is Tianda Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Tianda Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. pays a N/A dividend of HK$0.003 which represents an annual dividend yield of N/A. See more information on Tianda Pharmaceuticals Ltd. dividends here
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Tianda Pharmaceuticals Ltd. reported an EPS of -HK$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tianda Pharmaceuticals Ltd.
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September 2012, focuses on the research, development, manufacturing, and distribution of a wide array of pharmaceutical, biotechnology, and healthcare products. Its commercial reach extends across Mainland China, Hong Kong, and Australia. The company's diverse portfolio includes traditional Chinese medicines, chemical drugs, biological products, and medical appliances. These offerings target numerous therapeutic areas, such as cardio-cerebrovascular health, pediatric care, anti-flu and respiratory conditions, anti-infection, detoxification, and urological disorders. Health supplements are specifically marketed under the "Herb Valley" and "Tuokang" brand names. Furthermore, Tianda Pharmaceuticals is involved in the wholesale and retail of Chinese herbal medicines, traditional Chinese medicine (TCM) decoction pieces, and other Chinese medicinal products, provides Chinese medical services, and trades agricultural by-products.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―